Revolution Medicines (RVMD) Retained Earnings (2019 - 2026)

Revolution Medicines' Retained Earnings history runs 8 years deep, the most recent figure standing at -$622000.0 for Q1 2026.

• On a quarterly basis, Retained Earnings rose 99.97% year-over-year to -$622000.0 in Q1 2026; TTM through Mar 2026 was -$622000.0, a 99.97% increase from a year earlier, with the FY2025 full-year figure at $3.2 million, up 145.04% from the prior year.
• Retained Earnings retreated to -$622000.0 in Q1 2026 per RVMD's latest filing, from $3.2 million in the prior quarter.
• Across five years, Retained Earnings topped out at $3.2 million in Q4 2025 and bottomed at -$2.5 billion in Q3 2025.
• The 5-year median for Retained Earnings is -$2.4 million (2022), against an average of -$704.2 million.
• Across the five-year window, Retained Earnings sank 177079.33% in 2024 and jumped 145.04% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$701.3 million in 2022, then jumped by 100.08% to $544000.0 in 2023, then jumped by 142.83% to $1.3 million in 2024, then jumped by 145.04% to $3.2 million in 2025, then sank by 119.22% to -$622000.0 in 2026.
• Per Business Quant, the three latest RVMD Retained Earnings figures stand at -$622000.0 (Q1 2026), $3.2 million (Q4 2025), and -$2.5 billion (Q3 2025).